Simon J. F. Macdonald
GlaxoSmithKline
121 Papers
1.3K Citations
Simon J. F. Macdonald is an academic researcher from GlaxoSmithKline. The author has contributed to research in topics: Chemistry & Pyrrolidine. The author has an hindex of 34, co-authored 119 publications. Previous affiliations of Simon J. F. Macdonald include University of Oxford & The Hertz Corporation.
Chat about Author
Papers
The impact of aromatic ring count on compound developability – are too many aromatic rings a liability in drug design?
TL;DR: The fewer aromatic rings contained in an oral drug candidate, the more developable that candidate is probably to be; in addition, more than three aromatic rings in a molecule correlates with poorer compound developability and, thus, an increased risk of attrition in development.
770
The impact of aromatic ring count on compound developability: further insights by examining carbo- and hetero-aromatic and -aliphatic ring types.
TL;DR: Increasing aromatic ring count has a detrimental effect on human bioavailability parameters, and heteroaromatic ring count (but not other ring counts) has increased over time in marketed oral drugs.
386
Emerging therapeutic opportunities for integrin inhibitors.
TL;DR: In this article, the authors discuss the development of integrin inhibitors, particularly the challenges in developing inhibitors for integrins that contain an α-subunit, and suggest how these challenges could be addressed.
Factors determining the selection of organic reactions by medicinal chemists and the use of these reactions in arrays (small focused libraries).
TL;DR: This Minireview suggests some answers to questions about synthetic methodology and describes how the number of robust reactions available to the medicinal chemist has been tried to expand.
269
Dissecting fibrosis: therapeutic insights from the small-molecule toolbox.
Carmel B. Nanthakumar,Richard J. D. Hatley,Seble Lemma,Jack Gauldie,Richard P. Marshall,Simon J. F. Macdonald +5 more
TL;DR: The pharmacology and structural information for small molecules being evaluated for lung, liver, kidney and skin fibrosis is examined, and how these entities can inform, and probe, emerging insights into disease mechanisms, including the potential for future drug combinations are discussed.
215